Market capitalization | $780.33m |
Enterprise Value | $514.36m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.73 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-155.25m |
Free Cash Flow (TTM) Free Cash Flow | $-109.78m |
Cash position | $318.91m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
8 Analysts have issued a Erasca Inc forecast:
8 Analysts have issued a Erasca Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.88 -3.88 |
4%
4%
|
|
EBITDA | -151 -151 |
37%
37%
|
EBIT (Operating Income) EBIT | -155 -155 |
37%
37%
|
Net Profit | -159 -159 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Jonathan Lim |
Employees | 126 |
Founded | 2018 |
Website | www.erasca.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.